Fig. 4
From: Two successful decades of Swiss collaborations to develop new anti-malarials
The global portfolio of anti-malarial medicines (development pipeline and approved products). For definitions of the target compound profiles (TCPs) and target product profiles (TPPs) see [6, 8, 9]. 60P, 60° Pharmaceuticals; DNDi, Drugs for Neglected Diseases initiative; GSK: GlaxoSmithBeecham; ITM, Institute of Tropical Medicine; MMV, Medicines for Malaria Venture; U.: University. See the MMV website (http://www.mmv.org) for updated version of this Figure